🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Analyst maintains neutral stance on Cerence Inc. despite AI platform developments

EditorAhmed Abdulazez Abdulkadir
Published 10/09/2024, 10:48 PM
CRNC
-

On Wednesday, Baird reduced the price target for Cerence Inc . (NASDAQ:CRNC) to $5.00 from the previous $6.00, while keeping a Neutral rating on the stock. The adjustment follows Cerence's third-quarter fiscal year 2024 earnings report released in August, where the company announced new cost-cutting measures and provided more insight into its fiscal year 2025 plan. The plan indicates expectations of flat to declining revenue and single-digit EBITDA margins.

The company, which specializes in AI-driven assistance for vehicles, has also shared progress on generative AI and details about its upcoming full-stack AI platform. Cerence's approach to handling its soon-to-mature convertible notes was also highlighted, with management actively seeking solutions to mitigate potential costs.

The appointment of Brian Krzanich as the new CEO on October 7, 2024, marks a significant management change that is expected to provide a more comprehensive update in the fourth quarter fiscal year 2024. This update may include a refined strategy for fiscal year 2025.

Baird's cautious stance remains in place until there is clearer evidence of bookings that demonstrate Cerence's positioning and opportunities with next-generation AI. The firm acknowledges that the recent management change has been positively received by investors.

In other recent news, Cerence Inc. has undergone significant leadership changes with the appointment of Brian Krzanich as the new CEO, succeeding Stefan Ortmanns. Krzanich, a seasoned executive with a track record of driving growth at CDK Global (NASDAQ:CDK) Inc. and Intel (NASDAQ:INTC), joins Cerence at a time when the firm is maintaining its fourth quarter fiscal 2024 revenue forecast between $44 million and $50 million.

Additionally, Cerence has been the focus of a target price reduction by TD Cowen, from $12.00 to $10.00, despite maintaining a buy rating. This comes in the wake of Cerence's announcement of a substantial restructuring program, anticipated to yield savings between $35 million and $40 million.

In terms of earnings, Cerence reported third-quarter revenues of $70.5 million in fiscal year 2024, a 14% increase year-over-year. Despite a significant goodwill impairment charge of approximately $357 million, the company's non-GAAP profitability surpassed its own projections.

Looking ahead, Cerence anticipates net annualized cost savings between $35-40 million in the upcoming fiscal year through various cost reduction measures. The company's full-year revenue projection stands between $321 million and $327 million, with Q4 revenue estimated at $44-50 million.

InvestingPro Insights

Cerence Inc. (NASDAQ:CRNC) has been experiencing significant volatility in its stock price, which aligns with Baird's cautious stance. According to InvestingPro data, the company has seen a strong return of 35.38% over the last week and 27.55% over the last month, indicating recent positive sentiment. However, this comes after a substantial decline of 79.06% over the past year.

Despite the recent price target reduction by Baird, there are some positive indicators for Cerence. An InvestingPro Tip suggests that net income is expected to grow this year, which could potentially improve the company's financial position. Additionally, analysts predict that the company will be profitable this year, which may provide some reassurance to investors concerned about the flat to declining revenue expectations mentioned in the article.

It's worth noting that Cerence's revenue growth remains strong, with a 31.49% increase in the last twelve months as of Q3 2024. This growth, coupled with a healthy gross profit margin of 74.78%, suggests that the company's core business still has potential despite current challenges.

For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips for Cerence, providing a deeper understanding of the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.